- Home
- PRQR vs SABA Comparison
PRQR vs SABA Comparison
Compare PRQR & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.81
Company Overview
Basic Information| Metric | PRQR | SABA |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.4M | 225.6M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PRQR | SABA |
|---|---|---|
| Price | $1.81 | $8.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 306.7K | 117.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $7.72 |
| 52 Week High | $3.10 | $9.46 |
Technical Indicators
Market Signals| Indicator | PRQR | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 51.33 |
| Support Level | $1.65 | $7.97 |
| Resistance Level | $2.27 | $8.27 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 66.67 | 55.17 |
Price Performance
Historical Comparison PRQR
SABA
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.